InvestorsHub Logo
Followers 58
Posts 10124
Boards Moderated 1
Alias Born 09/21/2016

Re: georgejjl post# 413214

Monday, 05/01/2023 10:00:57 AM

Monday, May 01, 2023 10:00:57 AM

Post# of 461366
Eventually , S1R may be seen as Nature's Secret Sauce for AVXL , "Wonder Juice".

[quoteAnavex Life Sciences Corp.
Anavex Life Sciences Corp.
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, announced today it was granted a new U.S. Patent No. 11,622,955 entitled “SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY,” from the United States Patent and Trademark Office (USPTO), expanding Anavex’s coverage of treatment methods for ANAVEX®2-73 (blarcamesine), to the treatment of systolic hypertension, or lowering systolic blood pressure.

“We are extremely pleased with the expansion of the patent portfolio for ANAVEX®2-73 (blarcamesine) for the indication of hypertension which affects nearly half (47%) of adults in the United States, especially since elevated systolic blood pressure is a major health economy problem within our aging society,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “This new patent will add to our already robust patent portfolio relating to ANAVEX®2-73, and further demonstrate our strong overall commitment to protecting the full range of commercial opportunities of our product portfolio.”][/quote]
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News